Is it contraindicated to prescribe Vyvanse (lisdexamfetamine) to a patient with a past history of cocaine addiction for the treatment of attention-deficit hyperactivity disorder (ADHD)?

A history of cocaine addiction is NOT an absolute contraindication to prescribing Vyvanse for ADHD, but requires careful monitoring and controlled treatment conditions.

The key distinction is between recent/active stimulant abuse versus past substance use history. According to AACAP guidelines, stimulants are contraindicated in patients with a history of recent illicit use or abuse of stimulants, unless the patient is being treated in a controlled setting or can be supervised closely 1. However, patients who have histories of using or abusing other substances (such as alcohol, opiates, benzodiazepines, or sedatives) may have stimulants given to treat their ADHD 1. Even a history of abuse of stimulants may not represent an absolute contraindication, though such patients must be monitored even more carefully than would otherwise be the case 1.

Clinical Decision Algorithm

Assess the following factors:

1. Time since last cocaine use: Is this a former addiction (in sustained remission) or recent/active use?

   • If active or recent use: Contraindicated unless in controlled/supervised setting 1
   • If remote history with sustained remission: Not contraindicated, but requires enhanced monitoring 1

2. Current substance use status: Screen for any ongoing substance use

   • If household members have history of stimulant abuse, implement safeguards to prevent diversion 1

3. Treatment setting and supervision capability:

   • Can the patient be closely supervised?
   • Is there reliable medication accountability?
   • Can you ensure proper storage and prevent diversion?

Alternative Considerations

Non-stimulant medications may be preferred as first-line treatment in patients with substance use disorder history 2. Atomoxetine, guanfacine, or clonidine should be strongly considered as they:

• Have no abuse potential (non-controlled substances)
• May be regarded as more viable options due to lack of dopaminergic activity in nucleus accumbens/striatum 2
• Show efficacy in ADHD with comorbid substance use disorders 3

Research specifically on lisdexamfetamine (Vyvanse) shows:

• As a prodrug, LDX has attenuated abuse liability compared to immediate-release amphetamines 4, 5
• In individuals with history of substance use disorder, LDX showed similar efficacy and safety profiles to those without such history 6
• Adolescent stimulant therapy for ADHD was NOT associated with increased risk of later cocaine/methamphetamine use 7

If Prescribing Vyvanse Despite Cocaine History

Implement these safeguards:

• Document thorough substance use history and current remission status
• Establish clear treatment agreement regarding medication use and monitoring
• Schedule more frequent follow-up visits (at least monthly initially)
• Consider pill counts or prescription monitoring program review
• Involve family/support system in medication accountability when appropriate
• Screen for relapse at each visit
• Educate about proper storage and disposal 8
• Monitor for signs of misuse, diversion, or dose escalation 8

Critical Pitfalls to Avoid

Do not confuse "history of cocaine addiction" with "active stimulant abuse" - these carry different risk profiles. The FDA label for Vyvanse emphasizes assessing each patient's risk for abuse, misuse, and addiction before and during treatment 8, but does not list past substance use as an absolute contraindication.

Avoid withholding effective ADHD treatment based solely on remote substance use history when the patient is in sustained remission and can be appropriately monitored. Untreated ADHD itself may increase substance use risk.

Consider that cocaine users may have been self-medicating undiagnosed ADHD - some evidence suggests cocaine-dependent adults with ADHD reported therapeutic effects from cocaine during initial addiction phases 9. Proper ADHD treatment may actually reduce substance use risk in these individuals.